Clinical Trials Using Olaparib

Clinical trials are research studies that involve people. The clinical trials on this list are studying Olaparib. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 26-50 of 69

  • Olaparib in Treating Patients with High-Risk, Biochemically-Recurrent Prostate Cancer Who Have Undergone Surgery

    This phase II trial studies how well olaparib works in treating patients with high-risk prostate cancer that has had a rise in prostate-specific antigen (PSA) after surgery. A rise in the PSA is a sign that there are tumor cells remaining in the body. Olaparib may help lower PSA and may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: 4 locations

  • Olaparib and Tremelimumab in Treating BRCA1 or BRCA2 Mutation Carrier Patients with Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

    This phase I / II trial studies the side effects and best dose of tremelimumab when given together with olaparib in treating patients confirmed to carry a breast cancer 1 (BRCA1) or breast cancer 2 (BRCA2) germline mutation with ovarian, fallopian tube, or primary peritoneal cancer that has has come back. Tremelimumab is an antibody that may stimulate the immune system to fight cancer. Olaparib may block an enzyme that affects how cancer cells grow and divide. Giving tremelimumab and olaparib may work better in treating BRCA mutation carrier patients with ovarian, fallopian tube, or primary peritoneal cancer.
    Location: 3 locations

  • A Study of Pembrolizumab (MK-3475) With or Without Maintenance Olaparib in First-line Metastatic Squamous Non-small Cell Lung Cancer (NSCLC, MK-7339-008 / KEYLYNK-008)

    The current study will compare pembrolizumab (MK-3475) plus maintenance olaparib, vs. pembrolizumab plus maintenance olaparib placebo for the treatment of squamous NSCLC. The study's 2 primary hypotheses are: 1. Pembrolizumab plus maintenance olaparib is superior to pembrolizumab plus maintenance olaparib placebo with respect to progression-free survival (PFS) per RECIST 1.1 by blinded independent clinical review (BICR). 2. Pembrolizumab plus maintenance olaparib is superior to pembrolizumab plus maintenance olaparib placebo with respect to overall survival (OS).
    Location: 3 locations

  • Olaparib and Sapacitabine in Treating Patients with Metastatic or Unresectable BRCA Mutant Breast Cancer

    This phase Ib / II trial studies the side effects and best dose of sapacitabine when given together with olaparib and to see how well they work in treating patients with BRCA mutant breast cancer that has spread to other parts of the body or cannot be removed by surgery. Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as sapacitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving olaparib and sapacitabine may work better in treating patients with metastatic or unresectable BRCA mutant breast cancer.
    Location: 2 locations

  • Adavosertib with or without Olaparib in Treating Patients with Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

    This phase II trial studies how well adavosertib with or without olaparib work in treating patients with ovarian, primary peritoneal, or fallopian tube cancer that has come back (recurrent). Adavosertib and olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: 2 locations

  • AZD6738 and Olaparib in Treating Patients with Recurrent High Grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

    This phase II trial studies how well AZD6738 and olaparib work in treating patients with high grade ovarian, primary peritoneal, or fallopian tube cancer that has come back. AZD6738 and olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: 2 locations

  • Olaparib in Treating Patients with Metastatic or Advanced Urothelial Cancer with DNA-Repair Defects

    This phase II trial studies how well olaparib works in treating patients with urothelial cancer with DNA-repair defects that has spread to other places in the body (advanced or metastatic) and usually cannot be cured or controlled with treatment. Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: 6 locations

  • To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.

    This study is to assess the efficacy and safety of olaparib monotherapy versus olaparib in combination with an inhibitor of ATR (Ataxia-Telangiectasia Mutated (ATM) and Rad3-related protein kinase (AZD6738) and olaparib monotherapy versus olaparib in combination with an inhibitor of WEE1 (adavosertib [AZD1775]) in second or third line setting in patients with Triple-negative breast cancer (TNBC) prospectively stratified by presence / absence of qualifying tumour mutation in genes involved in the homologous recombination repair (HRR) pathway. Treatment arms are olaparib monotherapy, olaparib+AZD6738 and olaparib+adavosertib. The study subject population will be divided into Stratum A, Stratum B, and Stratum C. Due to the different schedules of administration of each of the treatment options as well as their different toxicity profiles, the study is not blinded. Study has two stage consent process- stage 1 consent (molecular screening for HRR defects) and stage 2 consent (main study). Patients with TNBC and with known qualifying BRCAm, non BRCAm HRRm and non HRRm status will be offered the option of consenting to the main part of the study within the 28-day screening period. Following the ISRC meeting on 17 April 2019 a recommendation was made to close the adavosertib+olaparib treatment arm across all biomarker strata. Patients receiving treatment with adavosertib+olaparib treatment were offered the opportunity to continue treatment on olaparib monotherapy at the approved dose (300 mg bd). Following the closure of this arm the total number of patients randomised will be lower (approximately 350 patients). Approximately 300 patients will be randomised (using randomisation ratio 1:1) to 2 ongoing treatment arms plus an additional 47 patients to a 3rd arm (olaparib+adavosertib) prior to the arm being discontinued.
    Location: 2 locations

  • Prexasertib and Olaparib in Treating Patients with Metastatic or Unresectable Solid Tumors

    This phase I trial studies the side effects and best dose of prexasertib and olaparib in treating patients with solid tumors that have spread to other places in the body or cannot be removed by surgery. Prexasertib and olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: 2 locations

  • Olaparib, Durvalumab, and Tremelimumab in Treating Patients with Recurrent or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer with BRCA1 or BRCA2 Mutation

    This phase I / II trial studies the side effects and best dose of olaparib when give together with durvalumab and tremelimumab and to see how well they work in treating patients with ovarian, fallopian tube, or primary peritoneal cancer with BRCA1 or BRCA2 genetic mutation that has come back (recurrent) or has not responded to treatment (refractory). Drugs, such as olaparib, may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and kill tumors cells with BRCA1 or BRCA2 mutation. Immunotherapy with monoclonal antibodies, such as durvalumab and tremelimumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving olaparib with durvalumab and tremelimumab may work better in treating patients with ovarian, fallopian tube, or primary peritoneal cancer.
    Location: 2 locations

  • A Phase I / II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors.

    The purpose of this study is to look at the effectiveness, safety, and antitumor activity of study drugs MEDI4736 in combination with olaparib (modules 1, 2, 3, 4, 5 and 7, 8 and 9) and MEDI4736 in combination with olaparib and bevacizumab (module 6 and 10). It will also examine what happens to the study drugs in the body and investigate how well the combination between MEDI4736, olaparib and bevacizumab is tolerated.
    Location: 2 locations

  • Ascending Doses of AZD6738 in Combination With Chemotherapy and / or Novel Anti Cancer Agents

    This is a modular, phase I / phase 1 b, open-label, multicentre study of AZD6738 administered orally in combination with cytotoxic chemotherapy regimens and / or novel anti-cancer agents, to patients with advanced malignancies. The study design allows an investigation of optimal combination dose of AZD6738 with other anti-cancer treatments, with intensive safety monitoring to ensure the safety of the patients. The initial combination to be investigated is AZD6738 with carboplatin. The second combination to be investigated is AZD6738 with Olaparib. The third combination to be investigated is AZD6738 with MEDI4736.
    Location: 2 locations

  • Cobimetinib or Olaparib in Treating Patients with Resectable Pancreatic Cancer

    This phase II trial feasibility study aims to determine how cobimetinib or olaparib works in patients with pancreatic cancer that can be removed by surgery. Validation of cobimetinib and olaparib molecular targets will be explored by comparing pre-treatment biopsies with post-treatment resection specimens. This knowledge will help design future biomarker driven trials to determine whether giving cobimetinib or olaparib will work better than standard treatments in patients with pancreatic cancer.
    Location: OHSU Knight Cancer Institute, Portland, Oregon

  • Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006)

    The current study will compare pembrolizumab (MK-3475) plus maintenance olaparib, v.s. pembrolizumab plus maintenance pemetrexed for the treatment of nonsquamous NSCLC. The study's 2 primary hypotheses are: 1. Pembrolizumab plus maintenance olaparib is superior to pembrolizumab plus maintenance pemetrexed with respect to progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors (RECIST 1.1) by blinded independent clinical review (BICR) and 2. Pembrolizumab plus maintenance olaparib is superior to pembrolizumab plus maintenance pemetrexed with respect to overall survival (OS).
    Location: 2 locations

  • Heat therapy (Hyperthermia) and Olaparib in Treating Breast Cancer Patients with Chest Wall Recurrences

    This phase I trial studies the side effects and best dose of olaparib when given with hyperthermia in treating patients with breast cancer that has come back in the chest wall. Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Hyperthermia is a a type of treatment in which body tissue is exposed to high temperatures to damage and kill cancer cells or to make cancer cells more sensitive to the effects of certain anticancer drugs. Giving olaparib and hyperthermia treatment may work better in treating patients with breast cancer that has come back in the chest wall compared to standard of care.
    Location: Thomas Jefferson University Hospital, Philadelphia, Pennsylvania

  • Olaparib in Treating Patients with Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer before Surgery

    This early phase I trial studies how well olaparib works in treating patients with newly diagnosed BRCA-mutant ovarian, primary peritoneal, or fallopian cancer before surgery. Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Durvalumab with or without Tremelimumab or Olaparib after Thoracic Radiation Therapy in Treating Patients with Extensive Stage-Small Cell Lung Cancer

    This phase I / Ib trial studies the side effects and how well durvalumab with or without tremelimumab or olaparib works after thoracic radiation therapy in treating patients with extensive stage-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as durvalumab and tremelimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. This study is being done to find out if all / any of the combinations of study treatment following thoracic radiation therapy will improve 6-month progression-free survival compared with a similar historical control group.
    Location: Moffitt Cancer Center, Tampa, Florida

  • Copanlisib, Olaparib, and Durvalumab in Treating Patients with Metastatic or Unresectable Solid Tumors

    This phase Ib trial studies side effects and best dose of copanlisib and olaparib when given together with durvalumab, and how well they work in treating patients with solid tumors that have spread to other places in the body (metastatic) or cannot be removed by surgery (unresectable). Copanlisib and olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving combinations of copanlisib and olaparib or copanlisib, olaparib, and durvalumab may work better in treating patients with solid tumors compared to usual treatments such as surgery, radiation, or other chemotherapy drugs.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Olaparib and Durvalumab in Treating Patients with Metastatic Triple Negative Breast Cancer

    This phase II study assesses the efficacy of the combination of olaparib and durvalumab in the treatment of patients with metastatic triple negative breast cancer (TNBC). Olabparib may stop growth of tumors cells by inhibiting some of the enzymes (ADP ribose polymerase [PARP]) needed for cell growth. Durvalumab, a monoclonal antibody, inhibits the growth and spread of tumors by stimulating the patient's antitumor immune response. Giving olaparib and durvalumab together may provide an effective method to treat patients with metastatic triple negative breast cancer.
    Location: OHSU Knight Cancer Institute, Portland, Oregon

  • Olaparib and Ceralasertib in Treating Patients with Metastatic Castration-Resistant Prostate Cancer

    This phase II trial studies how well olaparib and ceralasertib work in treating patients with castration-resistant prostate cancer that has spread to other places in the body (metastatic). Olaparib and ceralasertib work by blocking proteins important for repairing damage to deoxyribonucleic acid (DNA). When this damage cannot be repaired, tumor cells die. This trial is being done to test the effectiveness of olaparib and ceralasertib in treating patients with metastatic castration-resistant prostate cancer.
    Location: University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan

  • Olaparib for Treatment of Metastatic Kidney Cancer in Patients with DNA Repair Gene Mutations, the ORCHID Study

    This phase II trial studies how well olaparib works in treating patients with kidney cancer that has spread to other places in the body (metastatic) and have mutations in deoxyribonucleic acid (DNA) repair genes. It will also examine if olaparib is safe in these patients. PARPs are proteins that help repair damage to DNA, the genetic material that serves as the body’s instruction book. Changes (mutations) in DNA can cause tumor cells to grow quickly and out of control. PARP inhibitors like olaparib have been shown to keep PARP from working, so tumor cells may not be able to repair themselves, and may-stop growing.
    Location: Johns Hopkins University / Sidney Kimmel Cancer Center, Baltimore, Maryland

  • Ceralasertib with or without Olaparib in Treating Patients with Locally Advanced or Metastatic Solid Tumors

    This phase II trial studies how well ceralasertib works alone or in combination with olaparib in treating patients with solid tumors that have spread to nearby tissue or lymph nodes or other parts of the body. Ceralasertib and olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not known if giving ceralasertib with or without olaparib may work better in treating patients with solid tumors.
    Location: UCSF Medical Center-Mount Zion, San Francisco, California

  • Olaparib before Surgery in Treating Participants with Localized Prostate Cancer

    This phase II trial studies how well olaparib works in treating participants with prostate cancer that has not spread to other parts of the body. Olaparib may stop the growth of tumor cells by interfering with the activity of a substance called PARP, which is inside cells. Giving olaparib before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.
    Location: Fred Hutch / University of Washington Cancer Consortium, Seattle, Washington

  • Olaparib and Durvalumab in Treating Participants with Metastatic Triple Negative Breast Cancer

    This pilot phase I trial studies whether it is feasible to conduct a detailed molecular profile of triple negative breast cancer as part of a treatment strategy that asks whether or not we can lower the chance of breast cancer growing or spreading, by treating with a combination of PARP inhibitor how well (olaparib) and immune therapy (durvalumab). Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving olaparib and durvalumab may work better in treating participants with metastatic triple negative breast cancer.
    Location: OHSU Knight Cancer Institute, Portland, Oregon

  • Olaparib in People With Malignant Mesothelioma

    Background: The drug olaparib may stop cancer cells from fixing damage to their DNA. It has been approved to treat certain cancers in people that were born with a mutation in the BRCA gene. It has not been approved for treating mesothelioma. But some people with mesothelioma have mutations in a gene, BAP1 related to BRCA. Researchers want to see if olaparib can work in patients with mutations in this gene. They also want to see if works on mutations in other genes or patients without any mutations. They want to see if olaparib causes mesothelioma tumors to shrink. Objective: To study the effect of olaparib on mesothelioma. Eligibility: People ages 18 and older with malignant mesothelioma that has already been treated Design: Participants will be screened with Sample of tumor tissue or fluid Medical history Physical exam Blood, heart, and urine tests Scans and x-rays Participants will give blood and tissue samples. These will be genetically tested. The study will be done in 21-day cycles. Participants will take tables of the study drug 2 times each day. They will get information on what food and drugs to avoid during the study. They will get information about birth control. They will keep a diary of doses and symptoms. Participants will have blood and urine tests and scans every few weeks. Participants will be told any important genetic testing results. Participants will stay in the study until their disease gets worse or the participant or their doctor chooses to stop it. About 30 days after stopping the study drug, participants will have a follow-up visit. They will have a medical history, physical exam, blood tests, and scans. Some participants will continue to have scans every 6 weeks. ...
    Location: National Institutes of Health Clinical Center, Bethesda, Maryland